The study was comprised of four phases: TDF 300 mg with a boosted PI for 12 weeks (Phase 1), TAF 25 mg with a boosted PI for 12 weeks (Phase 2), TAF 25 mg with a boosted PI and ledipasvir/sofosbuvir for 4 weeks (Phase 3), and TAF 25 mg with a boosted PI for 12 weeks (Phase 4). CBC, complete blood count; CMP, comprehensive metabolic panel; LDV/SOF, ledipasvir/sofosbuvir; /r, with ritonavir; /c, with cobicistat. This figure appears in colour in the online version and black and white in the printed version of JAC.